Manish Sagar

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2300266/publications.pdf

Version: 2024-02-01

58 papers	4,105 citations	257450 24 h-index	161849 54 g-index
64 all docs	64 docs citations	64 times ranked	7697 citing authors

#	Article	IF	Citations
1	Severe Acute Respiratory Syndrome Coronavirus 2 Reinfection Associates With Unstable Housing and Occurs in the Presence of Antibodies. Clinical Infectious Diseases, 2022, 75, e208-e215.	5.8	16
2	Integrase Inhibitor Use Associated with Weight Gain in Women and Incident Diabetes Mellitus. AIDS Research and Human Retroviruses, 2022, 38, 208-215.	1.1	6
3	Antibody-dependent cellular cytotoxicity responses and susceptibility influence HIV-1 mother-to-child transmission. JCI Insight, 2022, 7, .	5.0	5
4	Vertical HIV-1 Transmission in the Setting of Maternal Broad and Potent Antibody Responses. Journal of Virology, 2022, 96, e0023122.	3.4	2
5	HIV-1 Transcription but Not Intact Provirus Levels are Associated With Systemic Inflammation. Journal of Infectious Diseases, 2021, 223, 1934-1942.	4.0	19
6	Recent endemic coronavirus infection is associated with less-severe COVID-19. Journal of Clinical Investigation, 2021, 131, .	8.2	277
7	Coronavirus Disease 2019 Mitigation Strategies Were Associated With Decreases in Other Respiratory Virus Infections. Open Forum Infectious Diseases, 2021, 8, ofab105.	0.9	13
8	Novel ELISA Protocol Links Pre-Existing SARS-CoV-2 Reactive Antibodies With Endemic Coronavirus Immunity and Age and Reveals Improved Serologic Identification of Acute COVID-19 via Multi-Parameter Detection. Frontiers in Immunology, 2021, 12, 614676.	4.8	13
9	The Effect of IL-6 Inhibitors on Mortality Among Hospitalized COVID-19 Patients: A Multicenter Study. Journal of Infectious Diseases, 2021, 223, 581-588.	4.0	6
10	Pre-existing infant antibody-dependent cellular cytotoxicity associates with reduced HIV-1 acquisition and lower morbidity. Cell Reports Medicine, 2021, 2, 100412.	6.5	15
11	Family matters for coronavirus disease and vaccines. Journal of Clinical Investigation, 2021, 131, .	8.2	2
12	HIV-1 Coreceptor Usage and Variable Loop Contact Impact V3 Loop Broadly Neutralizing Antibody Susceptibility. Journal of Virology, 2020, 94, .	3.4	14
13	Efficacy of Tocilizumab in Patients Hospitalized with Covid-19. New England Journal of Medicine, 2020, 383, 2333-2344.	27.0	1,102
14	Early administration of interleukin-6 inhibitors for patients with severe COVID-19 disease is associated with decreased intubation, reduced mortality, and increased discharge. International Journal of Infectious Diseases, 2020, 99, 28-33.	3.3	62
15	A new cell line for assessing HIV-1 antibody dependent cellular cytotoxicity against a broad range of variants. Journal of Immunological Methods, 2020, 480, 112766.	1.4	4
16	Clinical outcomes and inflammatory marker levels in patients with Covid-19 and obesity at an inner-city safety net hospital. PLoS ONE, 2020, 15, e0243888.	2.5	16
17	Title is missing!. , 2020, 15, e0243888.		0
18	Title is missing!. , 2020, 15, e0243888.		0

#	Article	IF	Citations
19	Title is missing!. , 2020, 15, e0243888.		0
20	Title is missing!. , 2020, 15, e0243888.		0
21	Condylomata Acuminata (Anogenital Warts) Contain Accumulations of HIV-1 Target Cells That May Provide Portals for HIV Transmission. Journal of Infectious Diseases, 2019, 219, 275-283.	4.0	6
22	Brief Report: Pulmonary Tuberculosis Is Associated With Persistent Systemic Inflammation and Decreased HIV-1 Reservoir Markers in Coinfected Ugandans. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 79, 407-411.	2.1	8
23	HIV-1 replicates and persists in vaginal epithelial dendritic cells. Journal of Clinical Investigation, 2018, 128, 3439-3444.	8.2	56
24	Neutralization and beyond: Antibodies and HIV-1 acquisition. Current Topics in Virology, 2018, 15, 73-86.	0.0	1
25	Maternal but Not Infant Anti-HIV-1 Neutralizing Antibody Response Associates with Enhanced Transmission and Infant Morbidity. MBio, 2017, 8, .	4.1	32
26	Humoral Immune Pressure Selects for HIV-1 CXC-chemokine Receptor 4-using Variants. EBioMedicine, 2016, 8, 237-247.	6.1	22
27	Antibodies and Acidic Environment Do Not Enhance HIV-1 Transcytosis. Journal of Infectious Diseases, 2016, 214, 1221-1224.	4.0	4
28	Comparison of the Metabolic Effects of Ritonavir-Boosted Darunavir or Atazanavir Versus Raltegravir, and the Impact of Ritonavir Plasma Exposure: ACTG 5257. Clinical Infectious Diseases, 2015, 60, 1842-1851.	5.8	67
29	Single genome amplification and standard bulk PCR yield HIV-1 envelope products with similar genotypic and phenotypic characteristics. Journal of Virological Methods, 2015, 214, 46-53.	2.1	15
30	Characterization of HIV-1 envelopes in acutely and chronically infected injection drug users. Retrovirology, 2014, 11, 106.	2.0	13
31	Efficacy and Tolerability of 3 Nonnucleoside Reverse Transcriptase Inhibitorâ€“Sparing Antiretroviral Regimens for Treatment-Naive Volunteers Infected With HIV-1. Annals of Internal Medicine, 2014, 161, 461.	3.9	225
32	Origin of the Transmitted Virus in HIV Infection: Infected Cells Versus Cell-Free Virus. Journal of Infectious Diseases, 2014, 210, S667-S673.	4.0	33
33	HIV-1 envelope replication and Î±4Î²7 utilization among newly infected subjects and their corresponding heterosexual partners. Retrovirology, 2013, 10, 162.	2.0	18
34	Early Infection HIV-1 Envelope V1-V2 Genotypes Do Not Enhance Binding or Replication in Cells Expressing High Levels of Î±4Î²7 Integrin. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 64, 249-253.	2.1	9
35	Long-Term Reduction in Peripheral Blood HIV Type 1 Reservoirs Following Reduced-Intensity Conditioning Allogeneic Stem Cell Transplantation. Journal of Infectious Diseases, 2013, 207, 1694-1702.	4.0	250
36	Transmembrane Domain Membrane Proximal External Region but Not Surface Unitâ€“Directed Broadly Neutralizing HIV-1 Antibodies Can Restrict Dendritic Cellâ€“Mediated HIV-1 Trans-infection. Journal of Infectious Diseases, 2012, 205, 1248-1257.	4.0	38

#	Article	IF	Citations
37	Previously Transmitted HIV-1 Strains Are Preferentially Selected During Subsequent Sexual Transmissions. Journal of Infectious Diseases, 2012, 206, 1433-1442.	4.0	71
38	Env sequence determinants in CXCR4-using human immunodeficiency virus type-1 subtype C. Virology, 2012, 433, 296-307.	2.4	20
39	Sensitivity Changes over the Course of Infection Increases the Likelihood of Resistance Against Fusion but Not CCR5 Receptor Blockers. AIDS Research and Human Retroviruses, 2012, 28, 1584-1593.	1.1	15
40	HIVâ€1 Transmission Biology: Selection and Characteristics of Infecting Viruses. Journal of Infectious Diseases, 2010, 202, S289-S296.	4.0	63
41	Evolution of CCR5 Antagonist Resistance in an HIV-1 Subtype C Clinical Isolate. Journal of Acquired Immune Deficiency Syndromes (1999), 2010, 55, 420-427.	2.1	23
42	Human Immunodeficiency Virus Type 1 V1-to-V5 Envelope Variants from the Chronic Phase of Infection Use CCR5 and Fuse More Efficiently than Those from Early after Infection. Journal of Virology, 2009, 83, 9694-9708.	3.4	41
43	In Vivo Fitness Cost of the M184V Mutation in Multidrug-Resistant Human Immunodeficiency Virus Type 1 in the Absence of Lamivudine. Journal of Virology, 2009, 83, 2038-2043.	3.4	76
44	Clinical implications of new findings in HIV basic research. HIV Therapy, 2009, 3, 351-360.	0.6	2
45	Selection of HIV Variants with Signature Genotypic Characteristics during Heterosexual Transmission. Journal of Infectious Diseases, 2009, 199, 580-589.	4.0	130
46	In Vivo Emergence of Vicriviroc Resistance in a Human Immunodeficiency Virus Type 1 Subtype C-Infected Subject. Journal of Virology, 2008, 82, 8210-8214.	3.4	110
47	Human Immunodeficiency Virus Type 1 V1-V2 Envelope Loop Sequences Expand and Add Glycosylation Sites over the Course of Infection, and These Modifications Affect Antibody Neutralization Sensitivity. Journal of Virology, 2006, 80, 9586-9598.	3.4	267
48	Diversity in HIV-1 Envelope V1â€“V3 Sequences Early in Infection Reflects Sequence Diversity Throughout the HIV-1 Genome But Does Not Predict the Extent of Sequence Diversity During Chronic Infection. AIDS Research and Human Retroviruses, 2006, 22, 430-437.	1.1	24
49	Effect of Contraceptive Methods on Natural History of HIV: Studies from the Mombasa Cohort. Journal of Acquired Immune Deficiency Syndromes (1999), 2005, 38, S18-S20.	2.1	24
50	No Evidence for Rapid Subtype C Spread within an Epidemic in Which Multiple Subtypes and Intersubtype Recombinants Circulate. AIDS Research and Human Retroviruses, 2005, 21, 1060-1065.	1.1	38
51	Selection for Human Immunodeficiency Virus Type 1 Envelope Glycosylation Variants with Shorter V1-V2 Loop Sequences Occurs during Transmission of Certain Genetic Subtypes and May Impact Viral RNA Levels. Journal of Virology, 2005, 79, 6528-6531.	3.4	241
52	Human Immunodeficiency Virus Type 1 (HIV-1) Diversity at Time of Infection Is Not Restricted to Certain Risk Groups or Specific HIV-1 Subtypes. Journal of Virology, 2004, 78, 7279-7283.	3.4	76
53	Identification of modifiable factors that affect the genetic diversity of the transmitted HIV-1 population. Aids, 2004, 18, 615-619.	2.2	60
54	Infection with Multiple Human Immunodeficiency Virus Type 1 Variants Is Associated with Faster Disease Progression. Journal of Virology, 2003, 77, 12921-12926.	3.4	133

#	Article	IF	Citations
55	Transmission ofHistoplasma capsulatumby Organ Transplantation. New England Journal of Medicine, 2000, 343, 1163-1166.	27.0	139
56	p53 and Tumor Necrosis Factor Î± Regulate the Expression of a Mitochondrial Chloride Channel Protein. Journal of Biological Chemistry, 1999, 274, 36488-36497.	3.4	119
57	Cooperation of p53 loss of function and v-Ha-ras in transformation of mouse keratinocyte cell lines. Molecular Carcinogenesis, 1998, 21, 50-61.	2.7	20
58	Refining the treatment of women with unstable anginaâ€"A randomized, doubleâ€blind, comparative safety and efficacy evaluation of integrelinâ„¢ versus aspirin in the management of unstable angina. Clinical Cardiology, 1996, 19, 869-874.	1.8	16